Raleigh, NC, United States of America

David Duffin

This inventor holds 1 USPTO granted patent. Top assignees: Affinergy Inc., Synthes USA, LLC. Active years: 2011.


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: David Duffin: Innovator in Bone-Targeted Drug Delivery

Introduction

David Duffin is a notable inventor based in Raleigh, NC (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the area of drug delivery systems targeting bone.

Latest Patents

David Duffin holds a patent titled "Methods and compositions for promoting localization of pharmaceutically active agents to bone." This patent describes compositions that include a family of peptides with binding specificity for bone. These compositions are utilized to create coating materials that facilitate the delivery of pharmaceutically active agents to bone. The applications of these coating compositions extend to methods related to bone implants, bone repair, and the treatment of bone-related diseases. He has 1 patent to his name.

Career Highlights

Throughout his career, David has worked with several prominent companies, including Affinergy Inc. and Synthes USA, LLC. His work has focused on advancing technologies that improve the efficacy of drug delivery systems.

Collaborations

David has collaborated with notable professionals in his field, including Doug Buechter and Hanne Gron. Their combined expertise has contributed to the development of innovative solutions in pharmaceutical applications.

Conclusion

David Duffin's work in the field of bone-targeted drug delivery exemplifies the impact of innovative thinking in pharmaceutical sciences. His contributions continue to influence advancements in the treatment of bone-related conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…